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INTRODUCTION 
Bladder cancer is a common genitourinary tract malignancy. Following 
prostatic adenocarcinoma, it represents the second most common tumour of 
urological malignancy in the world
1
. Urothelial tumours are cancers of the 
environment and advanced age. Bladder cancer is associated with old age and 
exposure to industrial toxins and smoking. It occurs most commonly in males than 
compared to female patients with ratio of 3:1 and is rare in the population less than 
40 years of age.  
According to WHO 2004 classification, urothelial tumours are categorized 
to muscle non-invasive and muscle invasive, based on invasion of detrusor muscle.  
Eighty percent of urothelial cancers are non-muscle invasive in nature and present 
with various types of growth pattern. Muscle-invasive tumour is defined by high 
grade and cancer cells invading through the lamina propria into the deeper muscle 
layers. Histologically, urothelial carcinoma constitutes 90 percent of bladder 
cancers, five percent are squamous cell carcinoma and less than five percent are 
adenocarcinoma or other types of tumours.   
The management of bladder cancer varies according to muscle non-invasive 
and muscle invasive nature of the cancer. Muscle non-invasive tumours are 
managed with transurethral resection (TUR) and intravesical immunotherapy / 
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chemotherapy. The treatment options for muscle invasive bladder cancer are 
radical cystectomy, radiation therapy, chemotherapy, or a combination. Thus it 
would be prudent to diagnose and differentiate between these two categories 
preoperatively by imaging techniques which helps in planning the treatment and in 
identifying the prognostic factors. 
Though contrast-enhanced computed tomography (CECT) and magnetic 
resonance imaging (MRI) are primarily used for diagnostic imaging, dynamic MRI 
has been found to be superior to CT for staging. With dynamic MRI, the primary 
drawback is the overstaging
2
. Contrast agents can have adverse effects and also can 
impair renal function. Contrast agents are contraindicated with raised renal 
parameters as there is risk of contrast induced nephropathy with iodine based 
agents used for CT or nephrogenic systemic fibrosis with gadolinium based 
contrast agents used for MRI. Diffusion-weighted MRI (DW-MRI) is a recent 
technical development in MRI which is noninvasive and based on the visualization 
of the molecular diffusion in biologic tissues. DW MRI is useful for depicting 
malignant tumors. Apparent diffusion coefficient (ADC), is a quantitative 
parameter calculated from the DW MRI which combines the effects of capillary 
perfusion and water diffusion in the extracellular extravascular space. ADC can 
characterize tumor grades and thus aids in determining prognosis. 
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AIM AND OBJECTIVES 
 
 
 To predict the pathological stage and grade of bladder cancer preoperatively 
by using Diffusion weighted Magnetic Resonance Imaging.  
 
 To study the correlation of Diffusion Weighted MRI findings with clinical, 
radiological and pathological findings. 
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REVIEW OF LITERATURE 
The bladder urothelium is made up of transitional cells, which can be 
transformed into various benign and malignant tumours. Bladder cancer is 
associated with advanced age and exposure to environmental toxins, primarily 
cigarette smoking. Total of 68810 new cases are diagnosed in United States and 
account for seven percent of all cancers. It is three times more common in males 
than in females and rare in age group less than 40 years. The median age for 
diagnosing a bladder tumour is seventy years and morbidity and mortality rate 
increase with advanced age.  
It is caused by hereditary abnormalities, industrial toxins
3
, cigarette 
smoking
4
, dietary deficiencies, chronic infection, inflammation, stone disease and 
chemoradiotherapy.  The risk factors are hereditary and race which is explained by 
the presence of disease in first-degree relatives of patients with bladder cancer 
have a twofold increased risk of developing bladder cancer themselves, but high-
risk of bladder cancer families are relatively rare. It most commonly occurs in 
Whites than compared with Africans-Americans. 
Bladder cancer most commonly occurs in males than compared to female 
patients with ratio of 3:1and rare in age less than 40 years, the reasons for the aged 
male prevalence are unclear but may be associated with large residual urine in the 
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bladder. Advanced age increases risk of cancer and most commonly present in the 
seventh decade of life. 
RISK FACTORS FOR UROTHELIAL TUMOUR: 
Cigarette smoking is one of the most important causes for development of 
bladder cancer. Smokers have a two to six fold risk compared to non-smokers, with 
respect to development of bladder cancer and subsequent recurrences
5
. Cigarette 
smoke contains the carcinogens like 4-aminobiphenyl and 2-naphthylamine. Slow 
hepatic acetylation of 4-aminobiphenyl by N-acetyltransferase and glutathione S-
transferase appear to increase urinary carcinogenic exposure of the urothelium
6
.  
Approximately twenty five percent of all urothelial cancers are related with 
occupational exposure to carcinogenic agents especially aromatic hydrocarbons. 
Aromatic amines bind with DNA and induce carcinogenesis. Usually a latent 
period of ten to twenty years occurs between toxin exposure and carcinogenesis
7
.  
Chemical agents commonly implicated for formation of carcinoma bladder 
are 4-Aminobiphenyl, Benzopyrene, Benzidine and β-Naphthylamine. These 
carcinogenic agents enter the system through skin absorption and inhalation. It can 
also caused by consumptions of large quantities of acetaminophen, 
chemotherapeutic agent like cyclophosphamide and pelvic radiotherapy. 
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Urinary bladder is storage organ, many micro nutrients and their end 
products have long duration of contact with urothelium. These micronutrients play 
the most important role in preventing the carcinogenesis. Various fresh vegetables 
and fruits specifically like carrots, apples, lemon, tomatoes and cruciferous 
vegetables contain various substances that are vital role in degradation 
carcinogenic agents. The molecules such as antioxidants, coenzymeQ and vitamins 
are preventing oxidative damage of DNA. 
Increased fluid intake prevents concentration carcinogenic agent’s contact 
with urothelium. Various studies showed increased fluid intake associated with 
lesser incidence of urothelial tumors compared with less fluid intake
8
.
 
Alcohol 
Alcohol intake is associated with various cancers like stomach, liver, oral 
cavity, oesophagus and larynx. Analysis from various literatures showed no 
positive correlation between alcohol intake and urothelial cancers
9
. 
Artificial sweetener 
Various studies in animals and humans have shown no association between 
consumption of artificial sweeteners and bladder cancer. 
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Drugs  
Acetaminophen is the metabolite of phenacetin. It is most commonly used 
for fever and analgesics purposes. Intake of phenacetin around five to fifteen 
kilograms over the ten years associated increased risk of bladder and renal 
cancers
4
. 
Inflammation/Infection 
Chronic infection and inflammation is a contributor to the development of 
squamous cell carcinoma. Patients infected with Schistosoma hematobium, human 
papilloma virus and B K virus are associated with squamous cell carcinoma. HPV 
virus encodes E6, E7 oncoproteins, which have influence on bladder cancer and its 
progression
10
. Previous gonorrhea infections associated with high risk for 
development of invasive cancer than noninvasive cancer
11
.  
Patients with long term indwelling catheters and stones have high risk of 
development of bladder cancer. Chronic inflammation of bladder mucosa by 
vesical calculus and other nidus including a long standing indwelling Foley’s 
catheter are associated with transformation to squamous cell carcinoma
12
.  
The process of carcinogenesis is due to production of nitrosamines by 
chronic urinary tract infections. These carcinogenic agents are produced by chronic 
infections with E.coli and pseudomonas organisims
13
.
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Radiation 
Radiation is rare cause of development of bladder cancer. It mostly follows 
treatment with radiotherapy for prostatic and cervical cancers. The latency period 
for development of carcinogenesis is from 15 to 30 years
14
. Radiation from more 
than 6 computed tomogram scan in a year is associated with secondary 
malignancies 
Chemotherapy 
Chemotherapy used to treat the cancers to destroy   the malignant cells and 
also cause damage to normal cells. Cyclophosphamide is the chemotherapeutic 
agent implicated in carcinoma bladder by means of direct relation to its duration 
and dose. The main mutagenic metabolite responsible for the development of 
cancer in patients who exposed to cyclophosphamide is  phosphoramide mustard
15
. 
Pathogenesis 
The bladder urothelium is multi-layered structure. It contains six cell layer 
thicknesses with umbrella cells. Most of the primary bladder cancers are malignant 
and of epithelial in origin. The urothelium is capable of transforming into different 
histopathological types of cancers
15
. Nearly ninety percent tumors of urinary 
bladder are transitional cell type and remaining 7% include squamous cell 
carcinoma, adenocarcinoma and undifferentiated tumors.  
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In Egypt and Middle East countries, Schistosomiasis infection is common 
and implicated for development of cancer. These patients develop squamous cell 
carcinoma of the bladder and constitute 55% to 80% of all bladder cancers. 
Secondary bladder cancers are mostly metastatic adenocarcinoma from gut, 
prostate, kidney and ovary. 
Premalignant lesions of bladder Cancer 
Precursor lesions are developed in a regular fashion from hyperplasia to 
cellular atypia to dysplasia and development of cancer.  
Hyperplasia 
Urothelial hyperplasia is defined by thickened mucosa and presence or 
absence of atypical cellular changes. The bladder urothelium contains greater than 
seven cells layer thickness and disorganization of cellular structure present. It is 
associated with low grade cancers and no increased risk of development of cancer.  
Atypia 
Reactive atypia histopathologically defined by large cells, nucleus 
abnormality and presence of abnormal nucleoli. It may be associated with 
infection, stones, previous instrumentation and intravesical therapies. 
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Dysplasia 
Urothelial dysplasia is histologically defined by presence of cohesive cells 
and abnormality in the nucleus. The urothelium is greater than seven cells 
thickness and nuclear changes include nucleus crowding, prominent nucleoli, and 
abnormal mitotic figures present. Umbrella cells are normally seen in dysplastic 
urothelium and absent in cases of carcinoma in situ. Dysplastic urothelium is 
indicator of urothelial cell instability and associated with transformation of high 
grade lesions. 
Urothelial Cancer Histology 
WHO graded the Non- muscle invasive bladder cancer into three categories. 
It includes 25 % of papillary urothelial neoplasia of low-malignant potential, fifty 
percent of low grade and twenty five percent of high grade lesions. The WHO 
2004 grading/2009 TNM staging of bladder cancer as in (Annexure). 
Carcinoma in situ (CIS) 
All CIS are high grade lesions. It is characterized as flat, red velvety and 
nonpapillary lesion, histologically characterized by loss of umbrella cells, 
noncohesive cellular structure, loss of cellular polarity and severe nuclear atypia. 
The genetic abnormalities include alterations in the RB, TP53, and PTEN genes. It 
is immunohistochemically stained for cytokeratin 20. It is a precursor lesion for all 
11 
 
invasive tumours. It spreads to underlying urothelium, distal ureters and prostatic 
urethra by direct invasion of tumour cells.  
Papillary urothelialneoplasia of low-malignant potential 
PUNLMP is a solitary, papillary growth with thin papillary stalk usually 
located at trigone of bladder. Histologically characterized by more than seven cells 
layer thick with minimal cytological atypia and nucleus is mildly enlarged.  
Low-grade bladder carcinoma: 
Low-grade lesions are characterized by papillary pattern with thin 
fibrovascular pedicle and branching fronds present, histologically characterized by 
large cellular size, atypical nucleus changes and mitotic figures. Lymphovascular 
spread occurs once tumour invades the lamina propria because it contains rich 
vascular network. 
High-grade Papillary Urothelial Cancer 
It is macroscopically characterized by fusion of papillary growth, with high-
grade lesions in the urothelium. Histologically characterized by altered growth 
pattern, pleomorphic cells, increased mitotic figures and exaggerated nuclei, more 
than 80% of these cancers will infiltrate the underlying structures if patient is not 
treated. 
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HPE above showing Low-grade papillary urothelial carcinoma 
 
HPE above showing High -grade papillary urothelial carcinoma 
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Muscle-invasive bladder cancer 
It is defined by high grade cancer cells infiltrating both lamina propria and 
detrusor muscle layer. It may also spread to adjacent perivesical tissues. Tumour 
spreads by direct tumour extension to detrusor muscle, prostate, urethra, ureteric 
orifices, uterus, vagina, perivesical fat, bowel and pelvic side walls. Lymphatic 
spread occurs into obturator and iliac group of lymph nodes. Blood borne 
metastasis commonly occurs into liver, lung, adrenal and bones. 
Clinical features 
Symptoms 
Main clinical symptom is total painless hematuria is usually seen in 85% of 
patients and microscopic hematuria occurs in all cases
16
. Patients with carcinoma 
in situ or invasive tumours present with urinary frequency, urgency and dysuria. 
Bladder cancer may cause symptoms of acute urinary retention, bladder outlet 
obstruction, suprapubic discomfort and suprapubic mass. It can also present with 
intractable hematuria or clot retention of urine. 
Patients with metastasis presented with systemic symptoms of anorexia, 
weight loss, jaundice, pathological fractures, pelvic pain or weakness. 
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Signs   
On clinical examination,patients have pallor due to blood loss and chronic 
renal impairment. Jaundice or hepatomegaly occurs due to liver metastasis. 
Abdominal examination may reveal palpable mass in suprapubic region in case of 
locally advanced disease. Digital rectal examination may reveal palpable mass 
above or involving the prostate. 
Laboratory investigation 
According to AUA guide lines patients with hematuria are evaluated with 
urine cytology, urethrocystoscopy and upper tract imaging. This guide line 
recommends consideration of reevaluation in low risk patients and obligatory 
reevaluation in high risk patients after six months. Those with high risk patients are 
age more than 40 years, history of gross hematuria, history of smoking, industrial 
toxin exposure, analgesic abuse, irritating voiding symptoms, pelvic radiation and 
prior Cyclophosphamide therapy.       
Routine urine examination  
It shows plenty of red blood cells on microscopic examination.   
Urine Cytology  
Cytological examination of urine is a widely accepted test and a first line 
investigation in high risk patients with hematuria and irritative urinary symptoms. 
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It involves microscopic examination of stained smears of urine.  It is used as 
diagnostic test to identify malignant cells and to monitoring the patients in 
postoperative follow up periods. Urine cytology has low sensitivity but high 
specificity for high-grade lesions and CIS.  
Urinary markers  
Urinary markers tests used to replace or complement the urinary cytology to 
diagnose the urothelial cancers. It has been developed to detect blood group 
antigens, tumour associated antigens, extracellular matrix proteins and growth 
factors.  
BTA test  
The human complement factor H-related protein detected by quantitative 
BTA TRAK and qualitative BTA stat tests. The sensitivity of these tests range 
from 50% to 80%, and the specificity ranges from 50% to 75%.  Compared with 
urinary cytology BTA test is more sensitive test to detect urothelial tumours. A 
false positive result occurs in patients with hematuria infection and inflammation. 
ImmunoCyt 
It is immunofluorescent assay and a hybrid of cytology. Three fluorescent 
labelled monoclonal antibodies are targeted at bladder cancer variant of CEA and 
two urinary bladder mucins. The Sensitivity of the test is 86% and specificity of 
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the test is 79 % in detecting urothelial cancers. It is not affected by benign 
conditions and its results are operator dependent 
 NMP22 Bladder Chek Test  
The test is used principles of identification of nuclear matrix protein 22 from 
urine. It is a portion mitotic apparatus released from nucleus during apoptosis of 
urothelial cells. NMP22 level are raised in patients with urothelial cancers
17
. A 
false positive result occurs in patients with hematuria, urinary tract infection, 
stones and post endoscopic procedures. The sensitivity of the test ranges from 
68.5% to 88.5% and specificity from 65.2% to 91.3%. The test is more sensitive 
than urine cytology but overall specificity less.  
UroVysion  
It is a cytology-based test, that utilises FISH of DNA probes” chosen to 
detect certain chromosomal foci.  The probes used to detect aneuploidy of 
chromosomes 3, 7, and 17.  The test got very high specificity to detect the 
urothelial tumors with currently available urinary markers
18
. The test will identify 
any chromosomal abnormalities before the development of clinical tumours. False 
positive results occur in patients with stones, inflammation and hematuria.  
17 
 
Serum markers 
Several studies evaluated the serum levels of CA-125, CA19.9 and 
carcinoembryonic antigen (CEA) with muscle invasive and metastatic tumours
19
. 
These markers were elevated in patients with extravesical disease and distant 
metastatic disease. Following chemotherapy the tumour responsiveness also 
correlated with serum marker levels
20
. 
Other serum markers 
Patients with muscle invasive and metastatic bladder cancers are associated 
elevated serum levels of various cytokines and growth factors. The growth factors 
are transforming growth factor beta-1 insulin growth factor-1and IGF binding 
protein3,  
E-cadherin  
It is a proteolytic derivative of cell adhesion molecule. Carcinoma bladder 
with loss of expression of E-cadherin molecules associated with high risk of cancer 
progression.  
The presence of circulating tumours cells associated with various stages of 
invasive tumours and metastatic disease. 
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Tissue Markers 
Patients with fifty per cent of high grade lesions are associated with altered 
levels of retinoblastoma gene and p53 gene. Loss of expression E-cadherin 
molecules associated with advanced pathologic stage and poor outcome after 
radical cystectomy.     Proliferation markers like as Ki-67 markers of angiogenesis 
and markers of apoptosis like Caspase 3, survivin, bcl-2 associated with poor 
outcomes.  
All patients with microscopic or macroscopic haematuria require 
investigation of upper urinary tracts, bladder, and urethra. It includes renal 
ultrasound, flexible cystoscopy, followed by intravenous urogram and contrast 
enhanced computed tomogram. 
Computed tomogram 
Plain and contrast enhanced computed tomogram is the first-line of 
radiological investigation in case of carcinoma bladder. It is more sensitive and 
faster than intravenous urogram and ultrasound in the detection of bladder 
tumours. CT findings suggestive of perivesical stranding and 
hydroureteronephrosis indicate muscle invasive tumours
21
.  
Hydroureteronephrosis can also be caused by tumour infiltrating the ureteric 
orifice or ureteric obstruction by enlarged lymphnode. It can also identify 
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involvement of adjacent structures like bowel and pelvic side walls. It provides 
imaging of the obturator, internal iliac, external iliac, common iliac and 
retroperitoneal lymphnodes. The presence of pelvic and retroperitoneal 
lymphnodes indicates muscle invasive nature of the tumour. 
Metastatic workup 
Chest X ray is more important for evaluation of secondary deposits in the 
lungs and mediastinal lymphadenopathy. Chest CT is performed any abnormality 
detected in chest X-ray, muscle invasive tumours, node positive disease and 
presence of solid organ metastasis.  
Bone scan indicated in high risk patients, new onset of skeletal pain and 
raised alkaline phosphatase. An MRI scan is useful in patients with history of 
contrast allergy and doubtful lesions in the bone scan. The new ferromagnetic 
nanoparticles used as contrast agent can be taken up by macrophages and detect as 
small as 3 mm metastatic foci. 
Positron emission tomography is used to identify patients with lymph nodal 
and distant metastatic disease in muscle invasive urothelial tumours. It is useful in 
monitoring and assesses tumour responsiveness to the chemotherapy and 
radiotherapy. 
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Magnetic Resonance Imaging (MRI) 
The excellent soft tissue resolution provided by MRI makes it superior to 
CT
22
. This helps in detecting adjacent organ involvement. On T1-weighted images, 
there is striking inherent contrast between the intermediate-signal-intensity bladder 
wall and bright perivesical fat. Dynamic MRI using contrast agents identifies the 
tumour better and stages the tumour better
23
. Perivesical involvement is identified 
using fat suppression techniques after enhancement
23
. Overstaging with dynamic 
MRI is seen in about 30% of cases
2
. The interval between the imaging procedure 
and TUR had not changed the accuracy of staging. According to Barentsz study, 
tumor T staging accuracy was 73%-96% of cases, and the nodal and metastatic 
staging accuracy was 73%-98% of cases
24
.  
DIFFUSION WEIGHTED MAGNETIC RESONANCE IMAGING  
(DW MRI) 
Diffusion-weighted imaging (DWI) is a recent technical development in the 
field of MRI, based on diffusion mobility of water molecules the tissue 
characteristics are obtained and these differ from T1 weighted or T2 weighted 
images. Brownian motion or the movement of the water molecules forms the basis 
of the diffusion weighted MRI
25
. It is the restriction to the movement of protons in 
the water molecules.  
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Restricted Diffusion = Bright 
 
The mobility of the protons is quantitatively measured with the parameter the 
apparent diffusion coefficient (ADC).  ADC depends on the environment where 
the protons are situated which is both qualitatively and quantitatively assessed. In 
tumors which are highly cellular and which has higher density of cell membranes 
there is restricted motions of proton molecules. DW MRI is used in clinical 
practice by measuring the signal intensity and the ADC values and the restricted 
motion of protons is seen as high signal intensity on DW MRI images with a 
corresponding low ADC
26
.  
DW MRI has been used as a diagnostic tool for a number of years in the 
field of neuroradiology
27
. In the hyperacute phase of cerebral ischemia, DW 
sequences play an important part in the diagnosis. The practical value of DW MRI 
is used to differentiate between the tumors and ischemia. Various studies have 
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shown that ADC values of malignant lesions of renal, prostatic, colonic, hepatic, 
and uterine cervical origin were lower than those of normal tissue or benign 
lesions
28,29,30,31,32
.  
Recently DW MRI has been used in extracranial organs both to monitor 
treatment response and tissue characterization and in evaluating function of 
different organs. Due to extreme sensitivity to motion which is from breathing and 
bowel movements and artefacts, which results in a high signal to noise ratio and 
did not permit to obtain thin-slice imaging, hence the role of DW MRI was initially 
limited to the cranial cavity. Takahara in his study has reported abdominal DW 
MRI with free breathing, made it possible to obtain images with the help of high-
quality multiplanar display with more adequate thin slices with multiple signal 
averaging, higher signal-to noise ratio
33
. 
Mastuki in his study retrospectively had demonstrated DW MRI can 
differentiate bladder cancers from the surrounding non neoplastic structures due to 
the presence of high signal intensity and low ADC values. Other studies have 
shown DW MRI is superior in staging organ-confined tumors compared to T2-
weighted sequences
26
. Takeuchi in his study has shown the superior staging 
accuracy of DW MRI and helps in predicting histologic grade of tumor with ADC 
values
34
.   
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MANAGEMENT OF BLADDER CANCER: 
To discuss the management of carcinoma bladder, after local staging 
workup, patient is subjected for transurethral resection of bladder tumour and it 
provides definitive histological diagnosis.  Cystoscopic appearance of infiltrating 
tumour includes size more than 5 cm, solid, sessile lesion and associated with 
bullous edema and ulceration.  
It is usually done under spinal or general anaesthesia and bimanual 
examination is necessary before and after TURBT. Obturator nerve block is 
indicated in those patients undergoing TURBT under regional anaesthesia
35
. It 
includes resection of tumour as well as resection of underlying detrusor muscle to 
assess the muscle invasion. Areas of red velvety patches around the tumours and 
prostatic urethra are biopsied if planned for reconstructive procedures. On 
histopathological examination careful observation is done for tumour type, grade, 
and presence or absence of detrusor muscle invasion. Grade of the tumour is  the 
most important prognostic factor. 
Re- TURBT is indicated in patients with incomplete initial resection, biopsy 
report shows absence of muscle tissue and definitive high grade lesions. It is done 
two to six weeks after initial TURBT.   
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After TURBT patients with solitary, primary, low grade lesions require 
immediate intravesical instillation of 40 mg of Mitomycin C.  Various 
chemotherapeutic agents administered intravesically like Adriamycin, thiotepa, 
epirubicin and gemcitabine. It will prevent the implantation of tumour cells and 
reduce the recurrence rate of tumour. 
Intravesical BCG is indicated in recurrent, multiple low grade tumors, T1 
tumors and CIS lesions. Dosing schedule of intravesical therapy includes both 
induction as well as maintenance regimen. Induction therapy comprises six weekly 
instillation 80 mg of BCG, followed by maintenance therapy including three 
weekly administrations at third, six month followed by every six months upto three 
years. It is absolutely contraindicated immediately after TURBT and with history 
of BCG sepsis, hematuria, traumatic catheterization and in immunocompromised 
patients and incontinent patients.  
Management of muscle invasive tumour 
Radical cystectomy with bilateral pelvic lymphadenectomy and urinary 
diversion is standard line of management in patients with muscle invasive 
urothelial tumors. The aim of therapy is complete removal of primary tumour and 
regional lymph nodes. It includes removal of the bladder, perivesical soft tissues, 
seminal vesicles and prostate in male patients.  
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In female patients along with bladder specimen, adjacent organs such as 
uterus, cervix, ovaries and anterior vagina are also removed.  Recent studies 
suggest that metastatic disease is uncommon in female internal organs and 
preservation of these organs provide good support for pelvic floor and neobladder. 
Pelvic lymph nodal metastasis is present in 20% to 25% of patients with 
urothelial tumours. Positivity in lymph nodes patients is associated with poor 
prognosis and reduced recurrence free survival compared with node negative 
patients.  
Boundaries of standard pelvic lymphadenectomy include laterally from 
genitofemoral nerve upto the internal iliac artery medially, Cooper ligament 
inferiorly, and common iliac artery superiorly. Extended lymph node dissection 
includes removal of lymphnodes upto bifurcation of aorta or inferior mesenteric 
artery. 
  American joint committee on cancer seventh edition manual describes nodal 
metastasis cranial to common iliac nodes denote metastatic disease. It recommends 
at least twelve lymphnodes should be removed. Various multicentre studies reports 
suggest that sensitivity of lymph node dissection is improved if number of nodes 
removed is between 15 and 30.  
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PATIENTS AND METHODS 
 
STUDY DESIGN 
Prospective cross-sectional diagnostic study  
PLACE OF STUDY 
This study was conducted in the Department of Urology, Rajiv Gandhi 
Government General Hospital, Madras Medical College, Chennai - 3. 
STUDY PERIOD 
 March 2013 to March 2014 
ETHICAL CLEARANCE 
The institutional ethical review board at our hospital approved the study. 
(No 33032013) 
INCLUSION CRITERIA 
All new patients presented with total hematuria were evaluated initially with 
ultrasonography of abdomen and pelvis and diagnosed cases of Carcinoma bladder 
were included. 
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EXCLUSION CRITERIA 
1. Patients with Previous TURBT  
2. Previously received intravesical therapy, systemic chemotherapy and 
external beam radiotherapy. 
METHOD OF STUDY 
Informed consent obtained from all the patients after explaining details of 
the study. All details were recorded in a proforma as an inpatient procedure. 
Analysis was done with the collected details prospectively. 
PATIENT EVALUATION 
All cases of carcinoma bladder was evaluated by clinical examination, renal 
function tests, urine cytology, imaging studies in the form of USG/CECT KUB. 
DW MRI of KUBU region was taken at the time of hospital admission. The TUR 
procedure was done within one week from the imaging procedure. 
MR Imaging 
Before obtaining DW MRI, bladder distension was necessary. MR imaging 
was performed with 1.5-T clinical MR systems (Magnetom Siemens Medical 
Solutions, Germany) with body phased-array coils using eight elements. MR 
images were initially taken with axial T2-weighted images of the kidney, ureter 
and urinary bladder region, using band width = 40 – 80 kHz, TE = 90–100  msec, 
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TR = 8000 msec, slice thickness of 3 to 5 mm, with intersecting gap of around 
1mm. Then DW MRI was taken by using parameters of band width = 142 kHz, TE 
minimum, TR = 8000 msec, slice thickness of 3 to 5 mm without intersecting gaps, 
with b values of 0 and 800 sec/mm
2
, upto 54 slices were obtained within 1 to 2 
minutes. 
ADC CALCULATIONS  
 ADC mapping is done at the console of the MRI. With linear regression 
analytic function the ADC values were calculated. The tumor boundaries were 
selected based on the appearance of tumor on T2-weighted imaging.  We also 
measured the ADC values of bladder tumours and surrounding structures i.e, the 
seminal vesicles, prostate, urine and normal urinary bladder wall. The mean ADC 
values of the tumours were measured and atleast two or three ADC measurements 
per lesion were taken depending upon the size of the lesion. 
Patients will then undergo Transurethral Resection of Bladder Tumour / 
cystectomy within one week after the imaging procedure. After the procedure the 
specimen was sent for histopathological examination. Then DW MRI findings 
were correlated with Clinical, Imaging and the pathological findings. 
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STUDY ANALYSIS 
The Statistical Package for the Social Sciences (SPSS) version 11.5, SPSS 
Inc, Chicago, IL, USA was used for the statistical analysis. Using multivariate 
analysis, the ADC values of bladder tumour, normal bladder wall, urine, seminal 
vesicle and prostate were compared. A p value of less than or equal to 0.05 was 
considered to be statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
 
OBSRVATIONS & RESULTS: 
 
 
 
Our total study group included,  
Total - 46 patients, 
Males – 42 (91.3%) and  
Females – 4 (8.7%) 
Male: Female Ratio was 10.5: 1  
 
42 ((91.3%) 
4(8.7%) 
Sex Distribution 
Male Female
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The above chart shows the age distribution of our study group which ranged 
from 28 to 76 years. The mean age was 59.6 ± 10.7 years. More than 50% of the 
patients were beyond 60 years of age. 
 
>30 yrs 31-40 yrs 41-50 yrs 51-60 yrs 61-70 yrs >70 yrs
1 
(2%) 
2 
(4%) 
7 
(15%) 
13 
(29%) 
19 
(42%) 
4 
(8%) 
Age vs No.of Patient Distribution 
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Of the total 46 patients, 10 (21.7%) had elevated renal parameters. They had 
bilateral hydroureteronephrosis. These patients were not administered with contrast 
agents during imaging and the pre-operative staging was done with DW MRI. Of 
the 10 patients, all had muscle invasive bladder cancer. 
 
10 
36 
0
5
10
15
20
25
30
35
40
RFT Elevated RFT Normal
RENAL FUNCTION TEST 
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 Tumor base was sessile in 28 patients (61%) and pedunculated in 18 (39%),  
 Tumor measurement ranged from 2 to 12 cms (mean 4.7 cms).  
 Histologic findings revealed urothelial carcinoma in all 46 patients (100%).  
 Muscle invasion by the malignancy was present in 27 patients (58.7 %), 
while the remaining 19 (41.3 %) had lamina invasion. 
18 (39%) 
28 (61%) 
PEDUNCULATED
SESSILE
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 Of the 46 patients low grade tumour was present in 30 (65%) and high grade 
tumour was present in 16 (35%) patients. 
 19 (41%) 
27 (59%) 
NMIBC
MIBC
30 (65%) 
16 (35%) 
Low Grade
High Grade
35 
 
 
 
 
Of the 46 patients,  
 19 (41.3%) patients who had T1 tumours following by TUR of tumour were 
subjected to intravesical immunotherapy,  
 27 (58.7%) patients had muscle invasive bladder tumour, of which 10 
(21.7%) were subjected to radical cystectomy and urinary diversion 
procedure, of the remaining 17 patients - 10 patients (21.7%) were not 
willing for definitive surgical procedure and 7 (15.2%) were unfit for major 
surgical procedure and was advised palliative radiotherapy.  
10 
17 
19 
0
2
4
6
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12
14
16
18
20
Radical cystectomy TUR biopsy TURBT
F
re
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o
 
Types of procedure 
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DW MRI images of the 46 patients were reviewed; the tumours were seen as 
high signal intensity (SI) compared to the other surrounding structures. There were 
no false-positive cases. The positive predictive values of DW imaging were 100% 
in terms of correctly detecting the carcinomas.  
 
 
Tumour mass showing high signal intensity 
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ADC values (×10
−3
mm
2
/sec) N Minimum Maximum Mean Std. Deviation 
ADC of Tumour 46 0.81 1.48 1.23 0.18 
ADC of Normal Bladder wall 46 1.67 2.18 1.91 0.09 
ADC of urine 46 3.02 4.12 3.61 0.32 
ADC of Seminal vesicle 46 1.67 2.22 1.90 0.13 
ADC of prostate 46 1.67 2.08 1.85 0.11 
      
The ADC values (×10−3 mm2/sec) ranged:  
for tumours from 0.81 to 1.48,  
for normal bladder wall from 1.67 to 2.18,  
for urine from 3.02  to 4.12 ,  
for seminal vesicle from 1.67 to  2.22  and  
for prostate from 1.67 to 2.08.  
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From the preceding table of the ADC values, the ADC value of urine was 
never in the range of the ADC value of tumours. In some patients, the ADC values 
of the prostate, seminal vesicles, or normal bladder wall had values which 
overlapped but did not overlap the ADC value of tumours.  This shows that a clear 
cutoff lies between the tumour ADC values and surrounding structures ADC 
values. By multivariate analysis showed that the  ADC values of the tumours was 
significantly lower compared to normal bladder wall (p < 0.001), urine (p < 0.001), 
prostate (p < 0.001), and seminal vesicle (p < 0.001).  
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 ADC values for histological subtypes of high grade were (n =16), 0.81 – 
1.34 [1.04 ± 0.10] and low grade were (n = 30), 1.23 – 1.48 [1.36 ± 0.06]. 
Thus there is a statistically significant difference for the ADC values of high 
grade and low grade tumours. 
 The ADC values of the tumours were correlated with the histopathological T 
and N stage but they did not show any significant correlation but it varied 
according to the grade of the tumour. 
 
Here as shown with the scatter plot above, ADC values did not show significant 
correlation between different tumour T stages and ADC values but between T1 and 
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
0 1 2 3 4
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D
C
 T
u
m
o
u
r 
T1 T2 T3 
MRI T Stage 
p value - 0.031 p value - 0.887 
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T3 there was significance because in T3 group there were 12 out of 16 (66%) 
patients of the high grade tumours. 
 
 
 
Here as shown with the scatter plot above, ADC values of tumour shows 
significant correlation between different tumour N stages and this significance is 
because in N2 group there were 6 out of 9 (66.6%) patients of the high grade 
tumours. 
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The DW MRI imaging findings and the histopathological findings of the 
tumour T staging were correlated and it is shown in the table below: 
 
 
DW-MRI T staging 
HPE 
Total P value 
T1 T2,T2,T3 
T1 18 0 18 
0.000 T2,T2,T3 1 27 29 
Total 19 27 46 
 
The MRI imaging in detecting T stage was showing: 
Sensitivity 94.4% 
Specificity 100.0% 
PPV 100.0% 
 
Thus with DW MRI images for diagnosing tumor T stage, p value was < 0.001 and 
was statistically significant. Thus the accuracy was determined for T staging. 
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The DW MRI imaging findings and the histopathological findings of the tumour 
Nodal staging were correlated and it is shown in the table below 
MRI N staging 
HPE 
Total P value 
N0 N2 
N0 36 0 36 
0.000 
N2 1 9 10 
Total 37 9 46 
 
The MRI imaging in detecting T stage was showing: 
Sensitivity 97.3% 
Specificity 100.0% 
PPV 100.0% 
 
 
Thus with DW MRI images for diagnosing tumor N stage, p value was < 0.001 and 
was statistically significant. Thus the accuracy was determined for N staging. 
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ADC Mapping showing tumour with low SI 
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DISCUSSION 
 
The urothelium of the bladder is traditionally considered tobe lined by 
transitional cells, which, as suggested by the name, can transform into a variety of 
benign and malignant tumors. Following prostatic adenocarcinoma carcinoma 
bladder represents second most common urological malignancies
1
. In literatures it 
is described as disease of environment and advanced age. It is three to four times 
common in males than compared to females and peak incidence occurs in seventh 
decade of life. The most common histologic sub type is urothelial carcinoma 
worldwide whereas in Egypt, squamous cell carcinoma is common due to 
endemicity of Schistosomiasis. Urothelial tumors are broadly divided into Non-
muscle invasive tumour and Muscle invasive tumour based on invasion of detrusor 
muscle fibers. 
It is proven that grade of the tumour is more important in predicting the 
prognosis rather than stage in Urothelial cancers.  The size of the tumour, 
multifocality, nature of the tumour and the presence or absence of angiolymphatic 
permeation also determines the prognosis. Bladder tumour has increased chance 
for recurrence after the primary treatment and this is mainly based on the 
prognostic factors. 
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 Under anaesthesia, cystoscopic assessment followed with transurethral 
resection (TUR) of bladder tumour provides pathological assessment of bladder 
tumour. TUR is essential to obtain histologic diagnosis but there are increased 
chances of underestimating the local extent of the tumour
36
. If histopathological 
report suggestive of Non-muscle invasive tumour these patients were managed 
with either intravesical therapeutic agents or high risk patients with aggressive 
therapies. Patients with muscle invasive tumours were categorized into organ 
confined disease, locally advanced disease and distant metastatic disease. The 
management of bladder cancer varies according to muscle non-invasive and 
muscle invasive nature of the cancer. Muscle non-invasive tumours are managed 
with transurethral resection (TUR) and intravesical immunotherapy / 
chemotherapy. The treatment options for muscle invasive bladder cancer are 
radical cystectomy, radiation therapy, chemotherapy, or a combination
37
.  
DW MRI is a recent technical development in the field of MRI, based on 
diffusion mobility of water molecules the tissue characteristics are obtained and 
these differ from T1 weighted or T2 weighted images. Brownian motion or the 
movement of the water molecules forms the basis of the diffusion weighted MRI
25
.  
The ADC, as a quantitative parameter is calculated from the DW MR images, 
combines the effects of water diffusion and capillary perfusion in the extracellular 
extravascular space. The mobility of the protons is quantitatively measured with 
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the parameter the apparent diffusion coefficient (ADC).  ADC depends on the 
environment where the protons are situated which is both qualitatively and 
quantitatively assessed
26
. In tumors which are highly cellular and which has higher 
density of cell membranes there is restricted motions of proton molecules. DW 
MRI is used in clinical practice by measuring the signal intensity and the ADC 
values and the restricted motion of protons is seen as high signal intensity on DW 
MRI images with a corresponding low ADC. Thus DW MRI gives details on 
diffusion and perfusion at the same time. DW MRI differentiates normal and 
abnormal structures of tissues better. 
DW MRI has been used as a diagnostic tool for a number of years in the 
field of neuroradiology
27
. In the hyperacute phase of cerebral ischemia, DW 
sequences play an important part in the diagnosis. The practical value of DW MRI 
is used to differentiate between the tumors and ischemia. Various studies have 
shown that ADC values of malignant lesions of renal, prostatic, colonic, hepatic, 
and uterine cervical origin were lower than those of normal tissue or benign 
lesions
28.29.30.31.32
.  
Recently DW MRI has been used in extracranial organs both to monitor 
treatment response and tissue characterization and in evaluating function of 
different organs. Due to extreme sensitivity to motion which is from breathing and 
bowel movements and artifacts, which results in a high signal to noise ratio and did 
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not permit to obtain thin-slice imaging, hence the role of DW MRI was initially 
limited to the cranial cavity. Takahara in his study has reported abdominal DW 
MRI with free breathing, made it possible to obtain images with the help of high-
quality multiplanar display with more adequate thin slices with multiple signal 
averaging, higher signal-to noise ratio
33
. 
Currently various radiological imaging are available to detect the 
pathological staging preoperatively. In our study, 46 patients were evaluated with 
blood tests, radiological imaging and DW MRI. After complete evaluation 18 
patients were found to have non-muscle invasive bladder tumour (NMIBC) and 28 
patients were diagnosed as muscle invasive tumour (MIBC) by DW MRI. Then 
patients underwent TURBT for histological diagnosis. After TURBT both tumour 
and deeper muscle tissues were sent to histopathological examination in separate 
containers. Histopathological examination showed 19 patients were non-muscle 
invasive bladder cancer, 27 were muscle invasive bladder cancer. Thus the 
correlation between DW MRI and histopathological examination had a sensitivity 
of 94.4%, specificity 100% and PPV of 100% and the diagnostic accuracy was 
statistically significant. 
Patients with muscle invasive bladder tumours were counseled for radical 
cystectomy with bilateral pelvic lymphadenectomy and urinary diversion. Of the 
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46 patients, 19 (41.3%) patients who had T1 tumours following by TUR of tumour 
were subjected to intravesical immunotherapy, 27 (58.7%) patients had muscle 
invasive bladder tumour, of which 10 (21.7%) were subjected to radical 
cystectomy and urinary diversion procedure, of the remaining 17 patients - 10 
patients (21.7%) were not willing for definitive surgical procedure and 7 (15.2%) 
were unfit for major surgical procedure and was advised palliative radiotherapy.  
 Postoperative report showed 19(41%) patients had NMBIC and 27 (59%) 
patients had MIBC. Of the 10 patients who had underwent radical cystectomy 9 
(90%) had lymph nodal metastasis but by DW MRI all had lymph nodal 
involvement. 
The feasibility of using DW MRI under free breathing as suggested by 
Takahara was tested by Matsuki et al for the detection of urinary bladder tumours 
in 15 patients. In their study, sensitivity, speficity and PPV of DW MRI were 
100% in detecting bladder cancers and all carcinomas had high SI relative to the 
surrounding non neoplastic structures
26
. The ADC value of the tumour was lower 
compared with that of the ADC values of surrounding structures and the urine.  In 
our study, all patients were evaluated with DW MRI before the biopsy and 
prospective evaluation of local staging and grading was done. All urinary bladder 
cancers showed high SIs and the ADC value of the carcinoma was lower compared 
ADC values of the surrounding normal structures. These results are similar to those 
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reported by Matsuki. The sensitivity, specificity and positive predictive values of 
diagnosis bladder carcinoma were 100% similar to previous results. In our study, 
invasion to the surrounding structures and nodal metastasis was clearly 
demonstrated with high SI of the tumors in comparison to the surroundings.  
Also there was no overlap between the ADC values of the tumors and the 
urine, but in some cases there was an overlap between the ADC values of the 
tumors and normal bladder wall, prostate or seminal vesicles. These findings are 
similar to those reported by Matsuki. The role of DW MRI in characterizing 
bladder tumours and a correlation, if any, with histological analysis of tumors 
could not be made since all the patients had urothelial carcinomas. The sensitivity, 
specificity and positive predictive values in our study were 100% in diagnosing 
patients of bladder cancers evaluated for total hematuria. Mastuki’s study was a 
retrospective study with small sample size. 
In Ahmed El study with 43 patients, they showed urinary bladder cancers 
showed high SIs in all cases and the ADC value of the carcinoma was lower 
compared with that of urine, the normal bladder wall, the prostate, and the seminal 
vesicles
38
. In our study there was no overlap of ADC values of the tumour with 
surrounding structures. The correlation of lower ADC values in high grade 
tumours in relation to low grade tumours which was significant was not assessed in 
Mastuki and Ahmed El study. 
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Takeuchi et al in their study showed the mean ADC of G3 tumors was 
significantly lower than that of G1 and G2 tumors all G3 tumors had an ADC less 
than 1.0 x 10−3  mm2/sec. and overall T-stage accuracy increased from 67% using 
T2W-MRI alone to 88% when DWMRI was added
34
. Our study also showed 
similar result but we had two groups one with low grade and the other with high 
grade tumours and ADC values of high grade tumours had mean of 1.04 ± 0.10 1.0 
x 10
−3
  mm
2
/sec. 
 Our study had limitations, with a mean tumor size of 4.7 cms and 
predominantly with large size tumours it would critical to assess more of small 
tumours and superficial tumours. Our study had a smaller sample size in relation to 
surgery and it would be critical to assess the local staging with a larger study 
group. Post chemotherapy and post radiotherapy patients were not assessed with 
DW MRI and it would be necessary to assess scars and reactive tissue and 
differentiate from the tumor tissue. 
Our study was a prospective study with adequate sample size other than the 
limitations as discussed above we found that DW MRI findings significantly 
correlate with histopathology in differentiating T1 from T2, T3, T4 and also in 
local nodal staging. Grading of bladder tumour could be assessed with DW MRI as 
high grade tumours had significantly lower ADC values compared to low grade 
tumours.  
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DW MRI images are obtained quickly and DW MRI technique does not 
need any contrast agents, hence can be used in patients with contrast allergy, and 
with compromised renal function. Thus DW MRI can be used preoperatively to 
effectively stage and grade the tumor and thus can help in planning the treatment. 
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CONCLUSIONS 
 
DW MRI findings significantly correlate with histopathology in 
differentiating non muscle invasive bladder tumours from muscle invasive bladder 
tumours and also in local nodal staging.  
Grading of bladder tumour could be assessed with DW MRI as high grade 
tumours had significantly lower ADC values compared to low grade tumours. 
Hence in the preoperative evaluation of bladder cancers, DW MRI is a 
useful diagnostic imaging study both for grading and local staging of bladder 
cancers. 
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2009 TNM CLASSIFICATION OF  
URINARY BLADDER CANCER 
 
 
T - Primary tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ: ‘flat tumour’ 
T1 Tumour invades subepithelial connective tissue 
T2 Tumour invades muscle 
T2a Tumour invades superficial muscle (inner half) 
T2b Tumour invades deep muscle (outer half) 
T3 Tumour invades perivesical tissue: 
T3a Microscopically 
T3b Macroscopically (extravesical mass) 
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, 
abdominal wall 
T4a Tumour invades prostate, uterus or vagina 
T4b Tumour invades pelvic wall or abdominal wall 
 
 
N - Lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, 
external iliac, or presacral) 
N2 Metastasis in multiple lymph nodes in the true pelvis (hypogastric, obturator, 
external iliac, or presacral) 
N3 Metastasis in common iliac lymph node(s) 
M - Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
  
WHO grading in 1973 and in 2004  
1973 WHO grading 
Urothelial papilloma 
Grade 1: well differentiated 
Grade 2: moderately differentiated 
Grade 3: poorly differentiated 
2004 WHO grading 
Flat lesions 
Hyperplasia (flat lesion without atypia or papillary aspects) 
Reactive atypia (flat lesion with atypia) 
Atypia of unknown significance 
Urothelial dysplasia 
Urothelial CIS 
Papillary lesions 
Urothelial papilloma (completely benign lesion) 
Papillary urothelial neoplasm of low malignant potential 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
 
 
INFORMED CONSENT FORM 
Title of the study:“EVALUATION WITH DIFFUSION WEIGHTED 
MAGNETIC RESONANCE IMAGING IN STAGING AND GRADING OF 
URINARY BLADDER CANCER” 
Name of the Participant: 
Name of the Principal Investigator: Dr. RAMKUMAR J 
Name of the Institution: Rajiv Gandhi Govt.General Hospital, Chennai -3. 
Documentation of the informed consent 
I _____________________________ have read the information in this form 
(or it has been read to me). I was free to ask any questions and they have 
been answered. I am over 18 years of age and, exercising my free power of 
choice, hereby give my consent to be included as a participant in 
“EVALUATION WITH DIFFUSION WEIGHTED MAGNETIC 
RESONANCE IMAGING IN STAGING AND GRADING OF 
URINARY BLADDER CANCER” 
 
1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past 3 months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately 
if I suffer unusual symptoms. 
8. I have not participated in any research study within the past 6 month(s) 
10. I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital. 
11. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent. 
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are 
publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
For adult participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name _________________________ Signature_________________ 
Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ 
Date________________ 
 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
INFORMATION TO PARTICIPANTS 
Sponsor: Nil 
Investigator: Dr.RAMKUMAR J 
Name of Participant: 
Institution: Madras Medical College and Rajiv Gandhi Government General 
Hospital 
Title: “EVALUATION WITH DIFFUSION WEIGHTED MAGNETIC 
RESONANCE IMAGING IN STAGING AND GRADING OF URINARY 
BLADDER CANCER” 
1. We are conducting the above study on Urinary bladder Cancer patients among 
patients attending Government General Hospital, Chennai  
2. You are being asked to participate in this study being conducted in Madras 
Medical College and Rajiv Gandhi Government General Hospital Chennai-3. 
3. You are invited to take part in this study. The information in this document is 
meant to help you decide whether or not to take part. Please feel free to ask if you 
have any queries or concerns.  
4. You will be investigated by DIFFUSION WEIGHTED MAGNETIC 
RESONANCE IMAGING of the abdomen in which you will undergo MRI 
imaging without any contrast administration and there will be no risks associated 
with the procedure and the findings will be correlated with other imaging and 
histopathological reports. 
The purpose of this study is to evaluate the stage and grade of urinary bladder 
cancer using Diffusion Weighted Magnetic Resonance Imaging. 
The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result in 
any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
Signature of investigator      Signature of participant  
Date: 
PATIENT PROFORMA 
 
 
Name:    Age:   Sex:    
 
Hospital No: 
 
Address:     
 
Date of admission: 
 
Date of Surgery:  
 
Date of Discharge: 
 
 Symptoms: 
 
                     Loin pain 
 
                     Hematuria 
 
                     Dysuria 
 
Duration of symptoms: 
 
Comorbid illness  : DM / HT / IHD / BA /TB 
 
PERSONAL HISTORY:  SMOKER / ALCIHOLIC 
 
CLINICAL EXAMINATION: 
General examination         
                                Pallor  
                                Jaundice 
   Gen.lymphadenopathy 
      Pedal edema 
 Systemic examination 
                                CVS: 
                                 RS: 
 Abdomen examination: 
 
 
External Genetalia: 
DRE: 
 
Laboratory evaluation 
CBC: 
 
RFT: 
UREA 
CREATININE 
      LFT: 
Serum Calcium: 
URINE Microscopy: 
 
URINE C/S: 
 
 
URINE CYTOLOGY: 
 
RADIOLOGICAL parameters 
 
X-ray KUBU: 
 
USG KUB: 
 
CECT scan: 
Tumor size 
Growth pattern 
Perivesical stranding 
Lymphadenopathy 
Adjacent organ involvement 
Distal metastasis 
MRI Findings of T2 Weighted Images & DW Images: 
Tumor size 
Growth pattern 
Perivesical stranding 
Lymphadenopathy 
Adjacent organ involvement 
Signal Intensity 
ADC Values of  
 
Bladder masses: 
Urine: 
Normal bladder wall: 
Seminal vesicle: 
Transition and peripheral zones of prostate: 
 Cystoscopic examination: 
           GROWTH PATTERN- PAPILLARY/SESSILE/ PEDUNCULATED 
           Presence of CIS 
 
Intraoperative findings 
Tumour size 
 Location 
Extravesical extenson 
Pelvic lymphadenopathy 
 
PATHOLOGICAL REPORT: 
Tumor size  
Grade  
Lymphovascular invasion  
Muscle invasion                                                                                                      
Lymph node 
Perivesical involvement 
 
 
 
 
 ABBREVATIONS 
 
WHO World Health Organization 
TUR  Transurethral Resection 
CECT  Contrast-Enhanced Computed Tomography 
MRI  Magnetic Resonance Imaging  
DW MRI  Diffusion-weighted MRI 
ADC  Apparent Diffusion Coefficient 
SI  Signal Intensity 
HPV  Human Papilloma Virus 
 
MuhŒ¢á x¥òjš got« 
MuhŒ¢á jiy¥ò 
“gutš fd¤j fhªj x¤jâ®î glkh¡fš _y« áWÚuf¥ig 
ò‰WnehÆ‹ nehŒ¡F¿ f£l« m¿tj‰fhd MŒî”  
MuhŒ¢á Ãiya« : áWÚÇaš Jiw,  
br‹id kU¤Jt¡ fšÿÇ k‰W« 
uhé› fhªâ muR bghJ kU¤Jtkid, br‹id. 
g¤F bgWtÇ‹ bga® : 
ghÈd« : 
g¤FbgwgtÇ‹ v© : 
g§F bgWgt® ïjid () F¿¡fî« 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu¤fŸ vd¡F És¡f¥g£lJ. 
v‹Dila rªnjf¤fis nf£fî«, mj‰fhd jFªj És¡f¤fis bgwî« 
thŒ¥gË¡f¥g£lJ. 
eh‹ ï›thŒÉš j‹Å¢irahfjh‹ g¤nf‰»nw‹. vªj fhuz¤âdhnyh 
vªj f£l¤âY« vªj r£l á¡fY¡F« c£glhkš eh‹ ï›thŒÉš ïUªJ Éy» 
bfhŸsyh« v‹W« m¿ªJ bfh©nl‹. 
ïªj MŒî r«gªjkhfnth, ïij rh®ªj nkY« MŒî nk‰bfhŸS« nghJ« 
ïªj MŒÉš g¤FbgW« kU¤Jt® v‹Dila kU¤Jt m¿¡iffis gh®¥gj‰F v‹ 
mDkâ njitÆšiy vd m¿ªJ bfhŸ»nw‹. eh‹ MŒÉš ïUªJ Éy»¡ 
bfh©lhY« ïJ bghUªJ« vd m¿»nw‹.  
ïªj MŒÉ‹ _y« »il¡F« jftšfisí«, gÇnrhjid Koîfisí« 
k‰W« á»¢ir bjhl®ghd jftšfisí« kU¤Jt® nk‰bfhŸS« MŒÉš 
ga‹gL¤â¡bfhŸsî« mij ãuRÇ¡fî« v‹ KG kdJl‹ r«kâ¡»‹nw‹.  
ïªj MŒÉš g¤F bfhŸs x¥ò¡bfhŸ»nw‹. vd¡F bfhL¡f¥g£l 
m¿îiufË‹go elªJ bfhŸtJl‹ ïªj MŒit nk‰bfhŸS« kU¤Jt mÂ¡F 
c©ikíl‹ ïU¥ng‹ v‹W cWâaË»nw‹. vdJ clš ey«ghâ¡f¥g£lhnyh 
mšyJ vâ®ghuhj tH¡fâ‰F khwhd nehŒ¡F¿ bj‹g£lhnyh clnd mij kU¤J 
mÂÆl« bjÇÉ¥ng‹ vd cWâ mË¡»nw‹. 
ïªj MŒÉš vd¡F ïu¤j«, áWÚ®, v¡Þnu, Þnf‹ k‰W« jir gÇnrhjid 
brŒJbfhŸs eh‹ KG kdJl‹ r«kâ¡»nw‹. 
 
g¤nf‰gtÇ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………… 
f£ilÉuš nuif 
g¤nf‰gtÇ‹ bga® k‰W« Éyhr« …………………………………………… 
MŒthsÇ‹ ifbah¥g« ……………….. ïl«…………….. njâ……………. 
MŒthsÇ‹ bga® ………………………………………… 
jftš got« 
cga¤jh®  : ïšiy 
MŒths® bga®  :  
g¤nf‰ghs® bga®  : 
MŒî brŒa¥gL« jiy¥ò : gutš fd¤j fhªj x¤jâ®î glkh¡fš 
_y« áWÚuf¥ig ò‰WnehÆ‹ nehŒ¡F¿ 
f£l« m¿tj‰fhd MŒî 
1. ïªj MŒî  
j¤fS¡F áWÚfu¥ig ò‰WnehŒ V‰g£L cŸsJ. mj‰F á»¢ir 
mË¡F« K‹ c¤fË‹ nehŒ¡F¿a f£l¤ij m¿a nt©o cŸsJ. 
mj‹bghU£L jh¤fŸ gutš fd¤j fhªj x¤jâ®î glkh¡fš _y« 
gÇnrhjid brŒJ nehŒF¿ f£l¤ij m¿ayh«. vdnt mj‰fhf gutš 
fd¤j fhªj x¤jâ®î glkh¡fš MŒÉ‰F r«kj« jUkhW bjÇÉ¤J¡ 
bfhŸ»nw‹.  
ïªj MŒÉš g¤FbgWtJ nehahËfË‹ brhªj ÉU¥g¤ânyna 
MF«. ïªj MŒitbah£o vªjÉjkhd rªnjf¤fS¡F« És¡f« bgw 
nehahËfS¡F cÇik cŸsJ. ïªj MŒÉ‹ KoîfŸ ïWâÆš 
ãuRÇ¡f¥gL«. 
 
 
 
 
g¤nf‰gtÇ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………… 
f£ilÉuš nuif 
g¤nf‰gtÇ‹ bga® k‰W« Éyhr« …………………………………………… 
MŒthsÇ‹ ifbah¥g« ……………….. ïl«…………….. njâ……………. 
MŒthsÇ‹ bga® ………………………………………… 
S. No Name Age Sex RFT MRI T STAGE HPE T STAGE MRI N STAGE HPE N STAGE TUMOUR APPEARANCE Signal intensity ADC Tumour ADC Normal wall ADC urine ADC Seminal vesicle ADC prostate Procedure HPE Grade HPE TYPE
1 Lakshmanan 67 m N T3 T3 N0 N0 PEDUNCULATED High 1.01 1.81 3.02 1.82 1.93 TUR biopsy High Urothelial
2 Narayanan 55 m N T1 T1 N0 N0 PEDUNCULATED High 1.23 2.03 4.12 2.22 1.89 TURBT Low Urothelial
3 Chinnaraj 50 M N T1 T1 N0 N0 PEDUNCULATED High 1.39 1.87 3.58 1.84 1.71 TUR biopsy Low Urothelial
4 Jallaludeen 70 M Raised T3 T3 N2 N2 SESSILE High 0.81 1.85 3.62 1.83 1.76 TUR biopsy High Urothelial
5 Raja 73 m N T1 T1 N0 N0 SESSILE High 1.32 1.79 3.71 1.86 2.01 TURBT Low Urothelial
6 Selvarasu 46 m N T3 T3 N0 N0 SESSILE High 1.04 1.94 3.42 1.98 1.82 TUR biopsy High Urothelial
7 Chinnasamy 65 m N T2 T3 N2 N2 SESSILE High 1.28 1.88 3.86 2.03 1.88 Radical cystectomy Low Urothelial
8 Velusamy 70 m N T3 T3 N2 N2 SESSILE High 1.33 1.96 3.18 1.97 1.98 Radical cystectomy Low Urothelial
9 Krishnan 68 m Raised T3 T3 N0 N0 SESSILE High 1.07 1.99 3.68 1.89 2.03 TUR biopsy High Urothelial
10 Kannan 40 m N T3 T3 N0 N0 SESSILE High 1.12 1.89 3.07 1.96 1.95 Radical cystectomy High Urothelial
11 Kathavarayan 60 m N T1 T1 N2 N0 PEDUNCULATED High 1.32 1.99 3.97 2.12 1.87 TURBT Low Urothelial
12 Kuppan 68 m Raised T3 T3 N0 N2 SESSILE High 0.98 1.86 3.15 1.96 2.01 TUR Biopsy High Urothelial
13 Rajendran 44 m n T3 T3 N0 N0 SESSILE High 1.36 1.99 3.51 2.13 1.96 Radical cystectomy Low Urothelial
14 Jagadeesan 75 m N T3 T3 N2 N2 SESSILE High 1.04 1.94 3.33 1.79 1.88 TUR biopsy High Urothelial
15 Jothikannu 55 f N T1 T1 N0 N0 PEDUNCULATED High 1.34 2.04 3.93 2.21 2.01 TURBT Low Urothelial
16 Duraisamy 55 m N T1 T1 N0 N0 PEDUNCULATED High 1.29 1.94 3.69 2.04 2.08 TURBT Low Urothelial
17 Samanan 63 m N T1 T1 N0 N0 PEDUNCULATED High 1.35 2.18 4.01 2.02 1.93 TURBT Low Urothelial
18 UMA MAHESWARI 40 F N T3 T3 N0 N0 SESSILE High 1.38 1.89 3.71 1.78 1.92 Radical cystectomy Low Urothelial
19 ANBALAGAN 55 M N T3 T3 N0 N0 SESSILE High 1.31 1.93 3.37 1.96 2.01 TUR Biopsy Low Urothelial
20 Veerappan 56 m N T3 T3 N2 N2 SESSILE High 1.04 1.98 3.63 2.03 1.78 Radical cystectomy High Urothelial
21 Subramani 57 M Raised T3 T3 N0 N0 SESSILE High 1.29 1.85 3.06 2.01 1.88 Radical cystectomy Low Urothelial
22 Kuppan 52 M N T1 T2 N0 N0 PEDUNCULATED High 1.33 1.88 4.01 1.95 1.67 TURBT Low Urothelial
23 Masilamani 65 M Raised T3 T3 N0 N0 SESSILE High 1.29 1.97 3.65 1.79 1.84 TUR BIOPSY Low Urothelial
24 Nagaraj 52 M N T1 T1 N0 N0 PEDUNCULATED High 1.43 2.02 3.44 1.89 1.79 TURBT Low Urothelial
25 Swaminathan 65 M N T3 T3 N0 N0 SESSILE High 1.07 1.87 3.39 1.71 1.84 TUR BIOPSY High Urothelial
26 Sudharshan 28 M N T1 T1 N0 N0 PEDUNCULATED High 1.35 1.93 3.28 1.85 1.74 TURBT Low Urothelial
27 Arumugam 70 M Raised T3 T3 N0 N0 SESSILE High 0.92 1.89 3.03 1.67 1.73 TUR BIOPSY High Urothelial
28 Doss 45 M N T3 T3 N0 N0 SESSILE High 1.34 1.96 3.54 1.94 1.78 TUR BIOPSY High Urothelial
29 Subramani 57 M N T3 T3 N0 N0 SESSILE High 1.28 1.85 3.26 1.79 1.93 Radical cystectomy Low Urothelial
30 Arjunan 65 M N T1 T1 N0 N0 SESSILE High 1.42 1.79 3.75 1.67 1.93 TURBT Low Urothelial
31 Ramakrishnan 50 M N T1 T2 N0 N0 PEDUNCULATED High 1.03 1.74 3.92 1.94 1.74 TURBT High Urothelial
32 Amsaveni 75 F Raised T3 T3 N2 N0 SESSILE High 1.07 1.92 4.01 1.67 1.82 TUR BIOPSY High Urothelial
33 Mahalingam 61 M N T1 T1 N0 N0 PEDUNCULATED High 1.39 1.87 3.85 1.85 1.73 TURBT Low Urothelial
34 Saradhammal 70 F Raised T3 T3 N2 N0 SESSILE High 1.07 1.96 3.48 1.89 1.78 TUR BIOPSY High Urothelial
35 Shanmugam 70 M N T3 T3 N0 N0 SESSILE High 1.36 1.84 3.58 1.98 1.79 TUR BIOPSY Low Urothelial
36 KrIshnamoorthy 68 M N T2 T2 N0 N0 SESSILE High 1.42 1.97 4.12 1.79 1.81 TURBT Low Urothelial
37 Desingu 65 M N T1 T1 N0 N0 PEDUNCULATED High 1.29 1.84 3.39 1.93 1.89 TURBT Low Urothelial
38 Patchyappan 59 M N T3 T3 N0 N0 SESSILE High 1.48 1.95 3.02 1.75 1.93 Radical cystectomy Low Urothelial
39 Ramu 65 M N T1 T1 N0 N0 PEDUNCULATED High 1.38 2.01 4.01 2.03 1.79 TURBT Low Urothelial
40 Rajkumar 50 M N T3 T3 N2 N2 SESSILE High 1.06 1.94 3.83 1.84 1.95 Radical cystectomy High Urothelial
41 Rajadurai 70 M Raised T3 T3 N0 N0 SESSILE High 1.38 1.84 3.95 1.79 1.68 TUR biopsy Low Urothelial
42 Anwar Basha 55 m N T1 T1 N0 N0 PEDUNCULATED High 1.46 2.05 3.63 1.88 1.74 TURBT Low Urothelial
43 Raman 50 M N T1 T1 N0 N0 PEDUNCULATED High 1.34 1.83 3.82 1.75 1.82 TURBT Low Urothelial
44 Sadhullah 57 M N T1 T1 N0 N0 PEDUNCULATED High 1.47 1.93 3.71 1.84 1.72 TURBT Low Urothelial
45 Ramasamy 76 M Raised T3 T3 N2 N2 SESSILE High 0.91 1.67 3.81 1.72 1.69 TUR biopsy High Urothelial
46 Balasundaram 70 M N T1 T1 N0 N0 PEDUNCULATED High 1.42 1.83 3.91 1.94 1.69 TURBT Low Urothelial
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